| Cat. No. |
Product Name |
Information |
| PC-42036 |
LY3177833
CDC7 inhibitor
|
LY3177833 is a potent and selective CDC7 inhibitor with IC50 of 3.3 nM. |
| PC-42060 |
AZD-5438
CDK1/2/9 inhibitor
|
AZD-5438 (AZD5438) potent and oral inhibitor of CDK1/2/9 with IC50 of 16/6/20 nM, respectively. |
| PC-42425 |
Senexin B
CDK8/CDK19 inhibitor
|
Senexin B (SNX2-1-165) is a highly potent, selective and orally available CDK8/CDK19 inhibitor with IC50 of 24-50 nM. |
| PC-42527 |
JNJ-7706621
CDK/Aurora inhibitor
|
JNJ-7706621 is a potent, dual CDK/Aurora kinase inhibitor with IC50 of 9/4/11/15 nM for CDK1/CDK2/Aurora A/Aurora B respectively. |
| PC-25402 |
TP-1287
CDK9 inhibitor
|
TP-1287 is a prodrug of Alvocidib (Flavopiridol, HMR-1275), is an orally active CDK9 inhibitor. |
| PC-25401 |
BRD6866
TFE3 inhibitor, CDK9 inhibitor
|
BRD6866 is a small molecule inhibitor of TFE3 transcription factor fusion activity with IC50 of 342 nM, shows dose-dependent chromatin trapping of TFE3, potent pan-CDK inhibitor across all families of CDKs, including both cell-cycle and transcriptional CDK9, suppresses tRCC cell growth. |
| PC-25380 |
LC-K2CAin-1
CDK2–Cyclin A2 inhibitor
|
LC-K2CAin-1 is a potent, highly selective CDK2-Cyclin A2 protein-protein interaction (PPI) inhibitor with IC50 of 59.57 nM in HTRF assays. |
| PC-25379 |
LC-K2CAin-3
CDK2–Cyclin A2 inhibitor
|
LC-K2CAin-3 is a potent, highly selective CDK2-Cyclin A2 protein-protein interaction (PPI) inhibitor with IC50 of 32.1 nM in HTRF assays. |
| PC-25359 |
CIRc-028
Cyclin A/B RxL inhibitor
|
CIRc-028 is a potent, in vivo-active, orally bioavailable dual cyclin A/B RxL inhibitor, inhibits cyclin A/B-RxL interactions and induces apoptosis in cancer cells with high E2F activity, induced spindle assembly checkpoint (SAC) activation and apoptosis in vivo. |
| PC-25358 |
CIRc-004
Cyclin A/B RxL inhibitor
|
CIRc-004 is a potent, cell-permeable dual cyclin A/B RxL inhibitor with IC50 of 0.13 and <0.02 uM for cyclin A1-CDK2 and cyclin B-CDK1, does not inhibit cyclin E1-CDK2, inhibits cyclin A/B-RxL interactions and induces apoptosis in cancer cells with high E2F activity. |
| PC-25129 |
YX0798
CDK9 inhibitor
|
YX0798 is a potent, selective and oral bioavailable CDK9 inhibitor with binding Kd of 0.28 nM, 16-50-fold more selective for CDK9 than CDK7, CDK3, or CDK4. |
| PC-25121 |
BEBT-209
CDK4 inhibitor
|
BEBT-209 is a potent, selective and orally active CDK4 inhibitor, 6-fold selective over CDK6. |
